⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for dabrafenib

Every month we try and update this database with for dabrafenib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene AlterationsNCT05876806
Cancer
Dabrafenib
Trametinib
19 Years - Seoul St. Mary's Hospital
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid TumorsNCT05868629
Rare Unresectab...
Non-investigati...
6 Years - Novartis
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNCT02097225
BRAF V600E Muta...
BRAF V600K Muta...
Metastatic Mali...
Metastatic Mela...
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Unresectable So...
Dabrafenib
Laboratory Biom...
Onalespib
Pharmacological...
Trametinib
18 Years - National Cancer Institute (NCI)
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid CancerNCT04544111
Thyroid Cancer
Thyroid Cancer,...
Papillary Thyro...
Follicular Thyr...
Hurthle Cell Tu...
Poorly Differen...
Hurthle Cell Th...
Trametinib
Dabrafenib
PDR001
18 Years - Memorial Sloan Kettering Cancer Center
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"NCT05299580
Melanoma
dabrafenib
Trametinib
18 Years - Fondazione Melanoma Onlus
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the BrainNCT02039947
Melanoma and Br...
Dabrafenib
Trametinib
18 Years - Novartis
Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEKNCT03553329
Unresecable Sta...
dabrafenib
18 Years - 100 YearsPoitiers University Hospital
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV MelanomaNCT02910700
Metastatic Mali...
Metastatic Mela...
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Unresectable Me...
Binimetinib
Dabrafenib
Encorafenib
Laboratory Biom...
Nivolumab
Pharmacological...
Trametinib
18 Years - M.D. Anderson Cancer Center
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D MelanomaNCT04310397
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Dabrafenib
Spartalizumab
Therapeutic Con...
Trametinib
18 Years - M.D. Anderson Cancer Center
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG TumorsNCT02684058
Diffuse Astrocy...
Anaplastic Astr...
Astrocytoma
Oligodendroglio...
Anaplastic Olig...
Glioblastoma
Pilocytic Astro...
Giant Cell Astr...
Pleomorphic Xan...
Anaplastic Pleo...
Angiocentric Gl...
Chordoid Glioma...
Gangliocytoma
Ganglioglioma
Anaplastic Gang...
Dysplastic Gang...
Desmoplastic In...
Papillary Glion...
Rosette-forming...
Central Neurocy...
Extraventricula...
Cerebellar Ipon...
Dabrafenib
trametinib
Carboplatin
Vincristine
12 Months - 17 YearsNovartis
Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary CraniopharyngiomaNCT05525273
Craniopharyngio...
Oral dabrafenib...
18 Years - Skane University Hospital
Dabrafenib and Trametinib for BRAF-inhibitor Pretreated PatientsNCT02296996
Malignant Melan...
Dabrafenib + Tr...
18 Years - Universitair Ziekenhuis Brussel
A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent SubjectsNCT01677741
Neoplasms, Brai...
Dabrafenib
12 Months - 17 YearsNovartis
Melanoma Metastasized to the Brain and SteroidsNCT03563729
Malignant Melan...
Pembrolizumab I...
Ipilimumab Inje...
Nivolumab Injec...
Encorafenib
Binimetinib
Dabrafenib
Trametinib
18 Years - Herlev Hospital
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant MelanomaNCT01989585
Clinical Stage ...
Clinical Stage ...
Malignant Solid...
Metastatic Mela...
Unresectable Me...
Biopsy
Biospecimen Col...
Computed Tomogr...
Dabrafenib
Echocardiograph...
Laboratory Biom...
Magnetic Resona...
Multigated Acqu...
Navitoclax
Pharmacological...
Trametinib
18 Years - National Cancer Institute (NCI)
E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)NCT03332589
Malignant Melan...
Brain Metastase...
E6201
E6201 plus dabr...
18 Years - Spirita Oncology, LLC
Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid CancerNCT04739566
Thyroid Gland A...
Dabrafenib
Trametinib
18 Years - Saint Petersburg State University, Russia
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple MyelomaNCT03091257
Multiple Myelom...
Dabrafenib
Trametinib
18 Years - Massachusetts General Hospital
Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and MidazolamNCT02082665
Cancer
Rosuvastatin10 ...
Midazolam 3 mg ...
Dabrafenib 75 m...
18 Years - 65 YearsGlaxoSmithKline
Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain MetastasesNCT02974803
Melanoma
Brain Metastase...
Dabrafenib
Trametinib
18 Years - Canadian Cancer Trials Group
Pediatric Long-Term Follow-up and Rollover StudyNCT03975829
Diffuse Astrocy...
Anaplastic Astr...
Astrocytoma
Oligodendroglio...
Anaplastic Olig...
Glioblastoma
Pilocytic Astro...
Giant Cell Astr...
Pleomorphic Xan...
Anaplastic Pleo...
Angiocentric Gl...
Chordoid Glioma...
Gangliocytoma
Ganglioglioma
Anaplastic Gang...
Dysplastic Gang...
Desmoplastic In...
Papillary Glion...
Rosette-forming...
Central Neurocy...
Extraventricula...
Cerebellar Lipo...
Neurofibromatos...
dabrafenib
trametinib
1 Year - Novartis
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete ResectionNCT04666272
Melanoma
dabrafenib
trametinib
18 Years - 100 YearsNovartis
Pediatric Long-Term Follow-up and Rollover StudyNCT03975829
Diffuse Astrocy...
Anaplastic Astr...
Astrocytoma
Oligodendroglio...
Anaplastic Olig...
Glioblastoma
Pilocytic Astro...
Giant Cell Astr...
Pleomorphic Xan...
Anaplastic Pleo...
Angiocentric Gl...
Chordoid Glioma...
Gangliocytoma
Ganglioglioma
Anaplastic Gang...
Dysplastic Gang...
Desmoplastic In...
Papillary Glion...
Rosette-forming...
Central Neurocy...
Extraventricula...
Cerebellar Lipo...
Neurofibromatos...
dabrafenib
trametinib
1 Year - Novartis
Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related OutcomesNCT03551626
Malignant Melan...
Dabrafenib
Trametinib
18 Years - Novartis
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)NCT01928940
Solid Tumours
dabrafenib
trametinib
20 Years - GlaxoSmithKline
Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant MelanomaNCT03754179
Melanoma
Dabrafenib
Trametinib
Hydroxychloroqu...
18 Years - Universitair Ziekenhuis Brussel
MCS110 With BRAF/MEK Inhibition in Patients With MelanomaNCT03455764
Melanoma
MCS110
Dabrafenib
Trametinib
18 Years - Dana-Farber Cancer Institute
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced MelanomaNCT02967692
Melanoma
Spartalizumab
Placebo
Dabrafenib
Trametinib
18 Years - Novartis
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal CancerNCT04294160
BRAF V600 Color...
Dabrafenib
LTT462
Trametinib
LXH254
TNO155
Spartalizumab
Tislelizumab
18 Years - Novartis
Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene AlterationsNCT05876806
Cancer
Dabrafenib
Trametinib
19 Years - Seoul St. Mary's Hospital
A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)NCT02130466
Melanoma
Solid Tumors
Pembrolizumab
Dabrafenib
Trametinib
Placebo
18 Years - Merck Sharp & Dohme LLC
Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung CancerNCT04507919
Small Cell Lung...
Dabrafenib
Trametininb
18 Years - 99 YearsNovartis
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and TrametinibNCT02382549
Melanoma
BRAF inhibitor
6MHP
MEK inhibitor
18 Years - University of Virginia
Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or TrametinibNCT02357732
Metastatic Mela...
Nivolumab
Trametinib
Dabrafenib
18 Years - University of Pittsburgh
A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent SubjectsNCT01677741
Neoplasms, Brai...
Dabrafenib
12 Months - 17 YearsNovartis
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by SurgeryNCT01947023
Metastatic Thyr...
Unresectable Th...
Biopsy
Biospecimen Col...
Computed Tomogr...
Dabrafenib
Dabrafenib Mesy...
Echocardiograph...
Lapatinib
Lapatinib Ditos...
Magnetic Resona...
Multigated Acqu...
Positron Emissi...
18 Years - National Cancer Institute (NCI)
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF AberrationNCT04201457
Low Grade Gliom...
High Grade Glio...
Low Grade Gliom...
Dabrafenib
Trametinib
Hydroxychloroqu...
1 Year - 30 YearsPediatric Brain Tumor Consortium
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain MetsNCT01721603
BRAFV600E Melan...
Dabrafenib
Gamma Knife Rad...
Trametinib
18 Years - University of California, San Francisco
A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive TumorsNCT01954043
Cancer
Dabrafenib 150 ...
Rabeprazole 40 ...
Rifampin 600 mg...
18 Years - GlaxoSmithKline
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 MutationNCT02231775
Stage IIIB Cuta...
Stage IIIC Cuta...
Dabrafenib
Laboratory Biom...
Therapeutic Con...
Trametinib
18 Years - M.D. Anderson Cancer Center
Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEKNCT03553329
Unresecable Sta...
dabrafenib
18 Years - 100 YearsPoitiers University Hospital
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable MelanomaNCT01767454
Solid Tumours
Dabrafenib
Trametinib
Ipilimumab
18 Years - GlaxoSmithKline
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid CancerNCT03975231
BRAF NP_004324....
BRAF V600K Muta...
Thyroid Gland A...
Dabrafenib
Intensity-Modul...
Trametinib
18 Years - City of Hope Medical Center
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLCNCT04452877
Carcinoma, Non-...
Dabrafenib
Trametinib
18 Years - Novartis
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG TumorsNCT02684058
Diffuse Astrocy...
Anaplastic Astr...
Astrocytoma
Oligodendroglio...
Anaplastic Olig...
Glioblastoma
Pilocytic Astro...
Giant Cell Astr...
Pleomorphic Xan...
Anaplastic Pleo...
Angiocentric Gl...
Chordoid Glioma...
Gangliocytoma
Ganglioglioma
Anaplastic Gang...
Dysplastic Gang...
Desmoplastic In...
Papillary Glion...
Rosette-forming...
Central Neurocy...
Extraventricula...
Cerebellar Ipon...
Dabrafenib
trametinib
Carboplatin
Vincristine
12 Months - 17 YearsNovartis
Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid CancerNCT03244956
Metastatic Radi...
Trametinib
Dabrafenib
131I
rhTSH
18 Years - Gustave Roussy, Cancer Campus, Grand Paris
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With MelanomaNCT02447939
Melanoma
Dabrafenib
Trametinib
18 Years - GlaxoSmithKline
Melanoma Metastasized to the Brain and SteroidsNCT03563729
Malignant Melan...
Pembrolizumab I...
Ipilimumab Inje...
Nivolumab Injec...
Encorafenib
Binimetinib
Dabrafenib
Trametinib
18 Years - Herlev Hospital
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete ResectionNCT04666272
Melanoma
dabrafenib
trametinib
18 Years - 100 YearsNovartis
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and TrametinibNCT02382549
Melanoma
BRAF inhibitor
6MHP
MEK inhibitor
18 Years - University of Virginia
Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLCNCT02672358
Non-Small-Cell ...
Dabrafenib
Trametinib
18 Years - Novartis
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive MelanomaNCT02083354
Cancer
Melanoma
Dabrafenib
Trametinib
18 Years - Novartis
A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive TumorsNCT01954043
Cancer
Dabrafenib 150 ...
Rabeprazole 40 ...
Rifampin 600 mg...
18 Years - GlaxoSmithKline
Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma PatientsNCT02625337
Metastatic Mela...
Pembrolizumab
Dabrafenib
Trametinib
Biopsy
Blood taking
18 Years - The Netherlands Cancer Institute
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by SurgeryNCT01947023
Metastatic Thyr...
Unresectable Th...
Biopsy
Biospecimen Col...
Computed Tomogr...
Dabrafenib
Dabrafenib Mesy...
Echocardiograph...
Lapatinib
Lapatinib Ditos...
Magnetic Resona...
Multigated Acqu...
Positron Emissi...
18 Years - National Cancer Institute (NCI)
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By SurgeryNCT01701037
Recurrent Melan...
Stage IIB Melan...
Stage IIC Melan...
Stage IIIA Mela...
Stage IIIB Mela...
Stage IIIC Mela...
Stage IV Melano...
dabrafenib
trametinib
laboratory biom...
18 Years - 90 YearsVanderbilt-Ingram Cancer Center
Melanoma Metastasized to the Brain and SteroidsNCT03563729
Malignant Melan...
Pembrolizumab I...
Ipilimumab Inje...
Nivolumab Injec...
Encorafenib
Binimetinib
Dabrafenib
Trametinib
18 Years - Herlev Hospital
Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant AmeloblastomaNCT06264778
Ameloblastoma
Dabrafenib
18 Years - 65 YearsShandong University
Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid CancerNCT04940052
Differentiated ...
Dabrafenib
Trametinib
Trametinib plac...
Dabrafenib plac...
18 Years - Novartis
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain MetsNCT01721603
BRAFV600E Melan...
Dabrafenib
Gamma Knife Rad...
Trametinib
18 Years - University of California, San Francisco
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib AloneNCT02027961
Melanoma
Durvalumab
Dabrafenib
Trametinib
18 Years - MedImmune LLC
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional MutationsNCT01726738
Stage III Melan...
Stage IV Melano...
Unresectable Me...
BRAF Mutant Mel...
BRAF inhibitor ...
18 Years - UNC Lineberger Comprehensive Cancer Center
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With MelanomaNCT02447939
Melanoma
Dabrafenib
Trametinib
18 Years - GlaxoSmithKline
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib AloneNCT02027961
Melanoma
Durvalumab
Dabrafenib
Trametinib
18 Years - MedImmune LLC
Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant AmeloblastomaNCT06264778
Ameloblastoma
Dabrafenib
18 Years - 65 YearsShandong University
Dabrafenib + Trametinib + PDR001 In Colorectal CancerNCT03668431
Metastatic Colo...
Dabrafenib
Trametinib
PDR001
18 Years - Massachusetts General Hospital
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryNCT01940809
BRAF V600E Muta...
BRAF V600K Muta...
Metastatic Mela...
Stage III Cutan...
Stage IIIA Cuta...
Stage IIIB Cuta...
Stage IIIC Cuta...
Stage IV Cutane...
Dabrafenib
Ipilimumab
Laboratory Biom...
Nivolumab
Trametinib
18 Years - National Cancer Institute (NCI)
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid CancerNCT04544111
Thyroid Cancer
Thyroid Cancer,...
Papillary Thyro...
Follicular Thyr...
Hurthle Cell Tu...
Poorly Differen...
Hurthle Cell Th...
Trametinib
Dabrafenib
PDR001
18 Years - Memorial Sloan Kettering Cancer Center
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 MutationNCT02231775
Stage IIIB Cuta...
Stage IIIC Cuta...
Dabrafenib
Laboratory Biom...
Therapeutic Con...
Trametinib
18 Years - M.D. Anderson Cancer Center
Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic MelanomaNCT03352947
Melanoma
Dabrafenib
Trametinib
18 Years - Cambridge University Hospitals NHS Foundation Trust
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the USNCT05260684
Melanoma
Encorafenib
Binimetinib
Vemurafenib
Cobimetinib
Dabrafenib
Trametinib
18 Years - Pfizer
Nilotinib Plus Dabrafenib/Trametinib in Metastatic MelanomaNCT04903119
Metastatic Mela...
BRAF Gene Mutat...
Nilotinib 100mg
Nilotinib 200mg
Nilotinib 300mg
Nilotinib 400mg
Dabrafenib
Trametinib
18 Years - University of Kentucky
Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.NCT04961619
Melanoma
dabrafenib
trametinib
18 Years - Novartis
Pediatric Long-Term Follow-up and Rollover StudyNCT03975829
Diffuse Astrocy...
Anaplastic Astr...
Astrocytoma
Oligodendroglio...
Anaplastic Olig...
Glioblastoma
Pilocytic Astro...
Giant Cell Astr...
Pleomorphic Xan...
Anaplastic Pleo...
Angiocentric Gl...
Chordoid Glioma...
Gangliocytoma
Ganglioglioma
Anaplastic Gang...
Dysplastic Gang...
Desmoplastic In...
Papillary Glion...
Rosette-forming...
Central Neurocy...
Extraventricula...
Cerebellar Lipo...
Neurofibromatos...
dabrafenib
trametinib
1 Year - Novartis
Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb StudyNCT02052193
Metastatic Mela...
Dabrafenib
Vemurafenib
18 Years - University Hospital Tuebingen
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060
Advanced Lympho...
Advanced Malign...
Bladder Carcino...
Breast Carcinom...
Cervical Carcin...
Colon Carcinoma
Colorectal Carc...
Endometrial Car...
Esophageal Carc...
Gastric Carcino...
Glioma
Head and Neck C...
Hematopoietic a...
Kidney Carcinom...
Liver Carcinoma
Lung Carcinoma
Lymphoma
Malignant Uteri...
Melanoma
Multiple Myelom...
Ovarian Carcino...
Pancreatic Carc...
Prostate Carcin...
Rectal Carcinom...
Recurrent Bladd...
Recurrent Breas...
Recurrent Cervi...
Recurrent Colon...
Recurrent Color...
Recurrent Esoph...
Recurrent Gastr...
Recurrent Gliom...
Recurrent Head ...
Recurrent Liver...
Recurrent Lung ...
Recurrent Lymph...
Recurrent Malig...
Recurrent Melan...
Recurrent Multi...
Recurrent Ovari...
Recurrent Pancr...
Recurrent Prost...
Recurrent Recta...
Recurrent Skin ...
Recurrent Thyro...
Recurrent Uteri...
Refractory Lymp...
Refractory Mali...
Refractory Mult...
Skin Carcinoma
Thyroid Gland C...
Uterine Corpus ...
Adavosertib
Afatinib
Afatinib Dimale...
Binimetinib
Biopsy
Biospecimen Col...
Capivasertib
Computed Tomogr...
Copanlisib
Copanlisib Hydr...
Crizotinib
Cytology Specim...
Dabrafenib
Dabrafenib Mesy...
Dasatinib
Defactinib
Defactinib Hydr...
Echocardiograph...
Erdafitinib
Fexagratinib
Ipatasertib
Laboratory Biom...
Larotrectinib
Larotrectinib S...
Magnetic Resona...
Multigated Acqu...
Nivolumab
Osimertinib
Palbociclib
Pertuzumab
PI3K-beta Inhib...
Radiologic Exam...
Radionuclide Im...
Relatlimab
Sapanisertib
Sunitinib Malat...
Taselisib
Trametinib
Trastuzumab
Trastuzumab Emt...
Ulixertinib
Vismodegib
18 Years - National Cancer Institute (NCI)
Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and DabrafenibNCT05988697
NSCLC
BRAF V600E Muta...
Advanced Cancer
Stage IIIB NSCL...
Stage IV NSCLC
Combind asprin ...
18 Years - 75 YearsDaping Hospital and the Research Institute of Surgery of the Third Military Medical University
E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)NCT03332589
Malignant Melan...
Brain Metastase...
E6201
E6201 plus dabr...
18 Years - Spirita Oncology, LLC
Nilotinib Plus Dabrafenib/Trametinib in Metastatic MelanomaNCT04903119
Metastatic Mela...
BRAF Gene Mutat...
Nilotinib 100mg
Nilotinib 200mg
Nilotinib 300mg
Nilotinib 400mg
Dabrafenib
Trametinib
18 Years - University of Kentucky
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in MelanomaNCT03149029
Metastatic Mela...
Pembrolizumab
Dabrafenib
Trametinib
18 Years - Massachusetts General Hospital
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: